title: Clinical impact of fluvoxamine-mediated long QTU syndrome.
authors.forename: Amir M
authors.initials: AM
authors.lastname: Nia
authors.forename: Kristina M
authors.initials: KM
authors.lastname: Dahlem
authors.forename: Natig
authors.initials: N
authors.lastname: Gassanov
authors.forename: Hansjörg
authors.initials: H
authors.lastname: Hungerbühler
authors.forename: Uwe
authors.initials: U
authors.lastname: Fuhr
authors.forename: Fikret
authors.initials: F
authors.lastname: Er
mesh_terms: D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications; D000072237:ERG1 Potassium Channel; D004827:Epilepsy / Q000150:complications; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors*; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009771:Obsessive-Compulsive Disorder / Q000150:complications / Q000188:drug therapy; D026902:Potassium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000150:complications; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D016666:Fluvoxamine; D026902:Potassium Channel Blockers; D017367:Selective Serotonin Reuptake Inhibitors